Skip to main content

Advertisement

Log in

Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

The BEYOND trial found that the addition of bevacizumab (B) to paclitaxel–carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed to evaluate the cost-effectiveness of adding B to first-line PC induction and continuation maintenance therapy from a Chinese perspective.

Methods

A Markov model was developed to estimate the cost and effectiveness of B + PC in the induction and maintenance therapy of patients with metastatic non-squamous NSCLC. Costs were calculated in the Chinese setting, and health outcomes derived from the BEYOND trial were measured as quality-adjusted life years (QALYs). A one-way sensitivity analysis was conducted to explore the impact of various parameters in the study.

Results

The B + PC treatment was more costly ($112,943.40 versus $32,171.43) and more effective (1.07 QALYs versus 0.80 QALYs) compared with the PC treatment. Adding B to the PC regimen for non-squamous NSCLC results in an incremental cost-effectiveness ratio of $299,155.44 per QALY, which exceeded the accepted societal willingness-to-pay threshold ($23,970.00) for China. In the sensitivity analysis, the duration of progression-free survival (PFS) for the B + PC group, the cost of the PFS state for B + PC group and the price of B were considered the most sensitive factors in the model.

Conclusions

The addition of B to first-line PC induction and maintenance therapy was not determined to be a cost-effective strategy for metastatic non-squamous NSCLC in China, even when an assistance program was provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):10–29.

    Article  Google Scholar 

  3. Bode AM, Dong Z, Wang H. Cancer prevention and control: alarming challenges in China. Natl Sci Rev. 2016;3(1):117–27.

    Article  PubMed  Google Scholar 

  4. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.

    Article  PubMed  Google Scholar 

  5. Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84.

    Article  PubMed  Google Scholar 

  6. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83(3):355–67.

    Article  CAS  PubMed  Google Scholar 

  7. Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer—recent advances and future perspectives. Int J Cancer. 2016;138(11):2549–61.

    Article  CAS  PubMed  Google Scholar 

  8. Hirsch FR, Bunn AJ. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009;10(5):432–3.

    Article  PubMed  Google Scholar 

  9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

    Article  CAS  PubMed  Google Scholar 

  10. Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase iii study of first-line carboplatin/paclitaxel + bevacizumab or placebo in chinese patients with metastatic or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–204.

    Article  CAS  PubMed  Google Scholar 

  11. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6(1):84–98.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Leung HW, Chan AL, Muo CH. Cost-effectiveness of gemcitabine + modern radiotherapy in locally metastatic pancreatic cancer. Clin Ther. 2016;38(5):1174–83.

    Article  PubMed  Google Scholar 

  13. Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009;45(8):1397–406.

    Article  CAS  PubMed  Google Scholar 

  14. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–51.

    Article  CAS  PubMed  Google Scholar 

  15. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line therapy for European patients with metastatic EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

    Article  CAS  PubMed  Google Scholar 

  16. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Phase III study of afatinib or cisplatin + pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.

    Article  Google Scholar 

  17. Ting J, Tien HP, Xiang P, Sugay A, Abdel-Sattar M, Wilson L. Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line therapy of metastatic EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health. 2015;18(6):774–82.

    Article  PubMed  Google Scholar 

  18. Goulart B, Ramsey SD. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer. Value Health. 2011;14(6):836–45.

    Article  PubMed  Google Scholar 

  19. Gridelli C, De Marinis F, Maio MD, Ardizzoni A, Belani CP, Cappuzzo F, et al. Maintenance therapy of metastatic non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer. 2012;76(3):269–79.

    Article  PubMed  Google Scholar 

  20. Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for metastatic nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1263–72.

    Article  PubMed  Google Scholar 

  21. Kumar G, Woods B, Hess LM, Treat J, Boye ME, Bryden P, et al. Cost-effectiveness of first-line induction and maintenance therapy sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer. 2015;89(3):294–300.

    Article  PubMed  Google Scholar 

  22. Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, et al. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for metastatic nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Clin Ther. 2013;35(1):54–65.

    Article  PubMed  Google Scholar 

  23. Barnett JC, Alvarez SA, Cohn DE, Leath CR, Myers ER, Havrilesky LJ. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary therapy of ovarian cancer. Cancer. 2013;119(20):3653–61.

    Article  PubMed  Google Scholar 

  24. Chan JK, Herzog TJ, Hu L, Monk BJ, Kiet T, Blansit K, et al. Bevacizumab in therapy of high-risk ovarian cancer—a cost-effectiveness analysis. Oncologist. 2014;19(5):523–7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to T. Xu or Q. Li.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, H., Xie, L., Zhan, M. et al. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer. Clin Transl Oncol 20, 286–293 (2018). https://doi.org/10.1007/s12094-017-1715-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1715-1

Keywords

Navigation